Physician profile
Michael Wang
NPI 1104820950
$6,874.56
in general payments reported to CMS, 2019-2025
27 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $1,289 · 2021: $565 · 2022: $1,018 · 2023: $1,186 · 2024: $761 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Entertainment: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.31 |
| Entertainment | $228.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $874.49 | 2022-2025 | Infuse, Alden Scleral Zenlens, Vyzulta |
| Alcon Vision LLC | $853.79 | 2019-2025 | Tryptyr, Precision7 |
| Sun Pharmaceutical Industries INC. | $768.87 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $651.04 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $633.26 | 2019-2021 | |
| Optos, INC. | $376.40 | 2020-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $355.18 | 2022-2025 | Tyrvaya |
| Coopervision INC. | $307.37 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $237.27 | 2019-2023 | Acuvue |
| Dompe US, INC. | $236.18 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $191.37 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $182.32 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $167.34 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $125.06 | 2020-2023 | |
| Genentech USA, INC. | $122.27 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $118.07 | 2023-2024 | Syfovre |
| Lombart Brothers, INC. | $103.78 | 2025 | Opd-III |
| Allergan, INC. | $103.34 | 2020-2022 | |
| Visionix USA, INC | $98.82 | 2022 | |
| Abbvie INC. | $97.22 | 2024-2025 | |
| Amgen INC. | $70.82 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $54.54 | 2022-2023 | Tepezza |
| Glaukos Corporation | $48.74 | 2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Mallinckrodt Hospital Products INC. | $42.17 | 2023-2024 | Acthar |
| Thea Pharma INC. | $20.51 | 2024 | Iyuzeh |
| Rxsight INC | $17.39 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Kala Pharmaceuticals, INC. | $16.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.